Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled study of SRP-4045 and SRP-4053 in Duchenne muscular dystrophy with open-label extension
NL-OMON42902Phase 3Withdrawn
- Sponsor
- Sarepta Therapeutics
- Start
- Nov 2016
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of casimersen and golodirsen in Duchenne muscular dystrophy (DMD) (4 arms), sponsored by Sarepta Therapeutics. Primary endpoint: Change from baseline in 6-minute walk test distance at Week 96. Planned start Nov 2016; status: withdrawn.
02
Drugs
casimersengolodirsen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NL-OMON42902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42902.